Soligenix develops and commercializes products for rare diseases with unmet medical needs. Their Specialized BioTherapeutics business segment is advancing the regulatory approval and commercialization of HyBryte™, a novel photodynamic therapy for cutaneous T-cell lymphoma. They also have development programs for psoriasis, inflammatory diseases, and gastrointestinal disorders. In their Public Health Solutions segment, Soligenix is actively developing vaccines for ricin toxin, filoviruses, coronaviruses, and antibiotic-resistant diseases. They have received government grant and contract funding for their vaccine programs. Soligenix's expertise lies in developing therapies for rare diseases, with a focus on preclinical, manufacturing, regulatory, and clinical aspects.